Skip to content

Safety and efficacy of Stereotactic Radiotherapy in brain metastasis in case of non small cell lung cancer .

IMPLEMENTING FRACTIONATED STEREOTACTIC RADIOTHERAPY IN OLIGOMETASTATIC BRAIN METASTASIS IN NON-SMALL CELL LUNG CANCER

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/02/040576
Enrollment
20
Registered
2022-02-24
Start date
Unknown
Completion date
Unknown
Last updated
2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D024- Carcinoma in situ of respiratory system, unspecified

Interventions

Intervention1: Fractionated Stereotactic Radiotherapy: it gives radiotherapy from many different angles around the body . The beam meet at the tumor. it delivers high dose to tumor and much lower dose

Sponsors

AIIMS NEW DELHI
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. NSCLC (pathologic confirmation) with 1-4 brain metastasis all smaller than 3 cm in diameter. 2. Adult patients (>=18 years of age), 3. Eastern Cooperative Oncology Group[ECOG] performance status 4. Graded Prognostic Assessment (GPA) >=1.5 5. All standard tumour-staging procedures necessary to define baseline extracranial disease status 6. Systemic treatment as per institute guidelines and physician discretion.

Exclusion criteria

Exclusion criteria: 1. Pregnant women 2. Inability to complete a magnetic resonance imaging scan with contrast 3. Prior resection of cerebral metastasis 4. Chemotherapy within 7 days of preregistration or planned chemotherapy during the radiotherapy 5. Prior cranial radiotherapy 6. Pacemaker or other MRI non-compatible metal in the body 7. Known allergy to gadolinium 8. Leptomeningeal metastases 9. Lesion located within 5 mm of the optic chiasm or within the brainstem 10. Inability to undergo contrast enhanced computed tomography 11. Inability to give consent

Design outcomes

Primary

MeasureTime frame
Intracranial tumour control rates. Neuro cognitive decline .Timepoint: Intracranial tumor control rate at 3 months Neuro congnitive assessment at 4 weeks.

Secondary

MeasureTime frame
â?¢ Cognitive outcomes for individual cognitive assessments: Defined as a decline of greater than 1 SD from baseline on cognitive tests (all tests are standardized based on published norms and transformed so that higher values represent improved cognition) at the 3-month post treatment evaluation.Timepoint: 3 monnths

Countries

India

Contacts

Public ContactSushmita Pathy

ALL INDIA INSTITUTE OF MEDICAL SCIENCES, NEW DELHI

drspathy@gmail.com9811898793

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026